Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 1
2016 1
2017 2
2018 3
2019 2
2020 5
2021 3
2022 6
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Développement des médicaments en pédiatrie : défis existants et recommandations.
Kaguelidou F, Ouèdraogo M, Treluyer JM, Le Jeunne C, Annereau M, Blanc P, Bureau S, Ducassou S, Fiquet B, Flamein F, Gaillard S, Hankard R, Laugel V, Laurent C, Levy C, Marquet T, Polak M, Portefaix A, Vassal G. Kaguelidou F, et al. Among authors: annereau m. Therapie. 2023 Jan-Feb;78(1):95-104. doi: 10.1016/j.therap.2022.12.002. Epub 2022 Dec 5. Therapie. 2023. PMID: 36543724 French. No abstract available.
Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
Cartry J, Bedja S, Boilève A, Mathieu JRR, Gontran E, Annereau M, Job B, Mouawia A, Mathias P, De Baère T, Italiano A, Besse B, Sourrouille I, Gelli M, Bani MA, Dartigues P, Hollebecque A, Smolenschi C, Ducreux M, Malka D, Jaulin F. Cartry J, et al. Among authors: annereau m. J Exp Clin Cancer Res. 2023 Oct 25;42(1):281. doi: 10.1186/s13046-023-02853-4. J Exp Clin Cancer Res. 2023. PMID: 37880806 Free PMC article.
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L, Sabio J, Poiraudeau L, Annereau M, Menssouri N, Helissey C, Déas O, Aglave M, Ibrahim T, Pobel C, Nobre C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Judde JG, Chauchereau A, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, Massard C, Friboulet L, Fizazi K, Besse B, Scoazec JY, Loriot Y. Bigot L, et al. Among authors: annereau m. Eur Urol Oncol. 2023 Oct 26:S2588-9311(23)00226-2. doi: 10.1016/j.euo.2023.10.011. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38433714
5-Azacitidine in patients with IDH1/2-mutant recurrent glioma.
Federici L, Capelle L, Annereau M, Bielle F, Willekens C, Dehais C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Idbaih A, Lemare F, de Botton S, Sanson M, Touat M. Federici L, et al. Among authors: annereau m. Neuro Oncol. 2020 Aug 17;22(8):1226-1228. doi: 10.1093/neuonc/noaa074. Neuro Oncol. 2020. PMID: 32215616 Free PMC article. No abstract available.
Identification of the Major Degradation Pathways of Selumetinib.
Bouchema TSE, Annereau M, Vieillard V, Boquet R, Coelho GA, Castelli F, Solgadi A, Paul M, Yagoubi N, Secretan PH, Do B. Bouchema TSE, et al. Among authors: annereau m. Pharmaceutics. 2022 Nov 30;14(12):2651. doi: 10.3390/pharmaceutics14122651. Pharmaceutics. 2022. PMID: 36559146 Free PMC article.
[Consortium for detection and management of lung damage induced by bleomycin].
Biya J, Stoclin A, Dury S, Le Pavec J, Mir O, Lazarovici J, Fermé C, Annereau M, Ekpe K, Massard C, Michot JM. Biya J, et al. Among authors: annereau m. Bull Cancer. 2016 Jul-Aug;103(7-8):651-61. doi: 10.1016/j.bulcan.2016.04.005. Epub 2016 May 27. Bull Cancer. 2016. PMID: 27241272 Review. French.
Design and stability of pediatric oral formulation of imatinib.
Hinterlang M, Gendron A, Fleury T, Rieutord A, Vrana A, Schlatter J, Annereau M. Hinterlang M, et al. Among authors: annereau m. J Oncol Pharm Pract. 2022 Mar;28(2):337-342. doi: 10.1177/1078155221991200. Epub 2021 Jan 31. J Oncol Pharm Pract. 2022. PMID: 33522386
Paediatric drug development and evaluation: Existing challenges and recommendations.
Kaguelidou F, Ouèdraogo M, Treluyer JM, Le Jeunne C, Annereau M, Blanc P, Bureau S, Ducassou S, Fiquet B, Flamein F, Gaillard S, Hankard R, Laugel V, Laurent C, Levy C, Marquet T, Polak M, Portefaix A, Vassal G. Kaguelidou F, et al. Among authors: annereau m. Therapie. 2023 Jan-Feb;78(1):105-114. doi: 10.1016/j.therap.2022.11.010. Epub 2022 Dec 5. Therapie. 2023. PMID: 36528416
Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.
Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL, Danlos FX, Dakdouki YE, Annereau M, Mariette X, Robert C, Cherif K, Marabelle A, Mateus C, Lambotte O. Michot JM, et al. Among authors: annereau m. Ann Rheum Dis. 2019 Jul;78(7):e67. doi: 10.1136/annrheumdis-2018-213677. Epub 2018 Jun 1. Ann Rheum Dis. 2019. PMID: 29858173 No abstract available.
26 results